To ensure inclusion of Japanese patients in global clinical studies for anticancer drugs, it is important to plan development strategies that take this into account from the early stages of clinical development. Too often the conflicting standards of Japanese regulatory agencies and global studies can cause delays or even the abandonment of anticancer drug development programs in Japan.
This white paper explores trends in anticancer drug development, requirements for approval and strategies for expediting these drugs to market in Japan.
Download the white paper.
